Compounds > 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide
Page last updated: 2024-09-03

4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and Alloxan Diabetes

4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with Alloxan Diabetes in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Li, H; Liu, Y; Wang, S; Wang, Z; Yin, W1
Cai, MB; Li, HG; Li, QK; Liu, Y; Wang, ZB; Yin, WD; Yu, J; Zhang, C; Zu, XH1
Tsutsumi, K; Yang, B; Yin, W; Yuan, Z1
Tsutsumi, K; Yin, W1
Fukuzawa, Y; Hara, T; Ikeda, H; Inoue, Y; Ishikawa, T; Kato, K; Kurokawa, T; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Ogawa, H; Okabayashi, N; Otake, K; Sakakibara, F; Tsutsumi, K1
Inoue, Y; Murase, T; Shima, A; Tsutsumi, K1
Inoue, Y; Tsutsumi, K; Yoshida, C1

Reviews

1 review(s) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and Alloxan Diabetes

ArticleYear
Lipoprotein lipase activator NO-1886.
    Cardiovascular drug reviews, 2003,Summer, Volume: 21, Issue:2

    Topics: Animals; Arteriosclerosis; Benzamides; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Enzyme Activators; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoprotein Lipase; Lipoproteins; Organophosphorus Compounds

2003

Other Studies

6 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and Alloxan Diabetes

ArticleYear
Ibrolipim attenuates early-stage nephropathy in diet-induced diabetic minipigs: Focus on oxidative stress and fibrogenesis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 129

    Topics: Animals; Antioxidants; Benzamides; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, High-Fat; Dietary Sucrose; Extracellular Matrix; Fibrosis; Gene Expression Regulation; Kidney; Male; Matrix Metalloproteinase 2; NADPH Oxidase 4; Organophosphorus Compounds; Oxidative Stress; Reactive Oxygen Species; Swine; Swine, Miniature; Transforming Growth Factor beta1

2020
Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs.
    Lipids in health and disease, 2011, Jul-16, Volume: 10

    Topics: Albuminuria; Animals; Benzamides; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dietary Fats; Drug Evaluation, Preclinical; Enzyme Assays; Gene Expression; Hypolipidemic Agents; Insulin; Kidney; Lipid Metabolism; Lipids; Lipoprotein Lipase; Male; Organ Size; Organophosphorus Compounds; Sucrose; Swine; Swine, Miniature

2011
Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits.
    Arzneimittel-Forschung, 2002, Volume: 52, Issue:8

    Topics: Animals; Arteriosclerosis; Benzamides; Blood Glucose; Body Weight; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Experimental; Eating; Enzyme Activators; Hypolipidemic Agents; Lipoprotein Lipase; Male; Organophosphorus Compounds; Rabbits; Sucrose; Triglycerides

2002
Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.
    Metabolism: clinical and experimental, 2004, Volume: 53, Issue:2

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzamides; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet; Dietary Fats; Enzyme Activators; Fatty Liver; Lipids; Lipoprotein Lipase; Male; Organ Size; Organophosphorus Compounds; Rats; Rats, Wistar

2004
Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats.
    Diabetes, 1995, Volume: 44, Issue:4

    Topics: Adipose Tissue; Animals; Benzamides; Cholesterol, HDL; Diabetes Mellitus, Experimental; Enzyme Induction; Gene Expression; Hypertriglyceridemia; Lipoprotein Lipase; Male; Myocardium; Organophosphorus Compounds; Rats; Rats, Wistar; RNA, Messenger

1995
Suppression of hyperlipidemia-associated cataracts in diabetic rats with the lipoprotein lipase activator NO-1886.
    Biological & pharmaceutical bulletin, 1996, Volume: 19, Issue:12

    Topics: Animals; Benzamides; Blood Glucose; Cataract; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Enzyme Activation; Hyperlipidemias; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Rats; Rats, Wistar; Risk Factors

1996